Country: United States
Language: English
Source: NLM (National Library of Medicine)
PHENTERMINE HYDROCHLORIDE (UNII: 0K2I505OTV) (PHENTERMINE - UNII:C045TQL4WP)
Preferred Pharmaceuticals Inc.
PHENTERMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE 15 mg
ORAL
PRESCRIPTION DRUG
Phentermine hydrochloride capsules are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m2 , or ≥ 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). Below is a chart of body mass index (BMI) based on various heights and weights. BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters. BODY MASS INDEX (BMI), kg/m2 Height (feet, inches) Weight (pounds) 5'0" 5'3" 5'6" 5'9" 6'0" 6'3" 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43
Phentermine hydrochloride capsules are supplied as: Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight container as defined in the USP, with a child-resistant closure (as required). Keep out of the reach of children.
Abbreviated New Drug Application
PHENTERMINE HYDROCHLORIDE- PHENTERMINE HYDROCHLORIDE CAPSULE PREFERRED PHARMACEUTICALS INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE PHENTERMINE HYDROCHLORIDE CAPSULES, USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR PHENTERMINE HYDROCHLORIDE CAPSULES, USP. PHENTERMINE HYDROCHLORIDE CAPSULES, USP FOR ORAL USE CIV INITIAL U.S. APPROVAL: 1959 INDICATIONS AND USAGE Phentermine hydrochloride is a sympathomimetic amine anorectic indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m , or ≥ 27 kg/m in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). (1) The limited usefulness of agents of this class, including phentermine hydrochloride, should be measured against possible risk factors inherent in their use. (1) DOSAGE AND ADMINISTRATION • • • DOSAGE FORMS AND STRENGTHS • • • CONTRAINDICATIONS • • • • • • • • • WARNINGS AND PRECAUTIONS • • • • • • • • • ADVERSE REACTIONS Adverse events have been reported in the cardiovascular, central nervous, gastrointestinal, allergic, and endocrine systems. (6) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT LANNETT COMPANY, INC. AT 1-800-325-9994 OR FDA AT 1-800-FDA- 1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS • • • • 2 2 Dosage should be individualized to obtain an adequate response with the lowest effective dose. (2) Late evening administration should be avoided (risk of insomnia). (2) Phentermine hydrochloride capsules can be taken with or without food (12.3) Powder-filled capsules containing 15 mg phentermine hydrochloride. (3) Powder-filled capsules containing 30 mg phentermine hydrochloride. (3) Pellet-filled capsules containing 30 mg phentermine hydrochloride. (3) History of cardiovascular disease Read the complete document